Innoviva (INVA) Long-Term Investments (2012 - 2026)
Innoviva (INVA) posted Long-Term Investments of $413.1 million for Q1 2026, up 2.12% on a QoQ basis from $404.5 million in Q4 2025, and up 41.9% year-over-year from $291.1 million in Q1 2025.
Innoviva (INVA) Long-Term Investments (2012 - 2026) Analysis & Trends
Innoviva's Long-Term Investments history runs 11 years deep, the most recent figure standing at $413.1 million for Q1 2026.
- Quarterly Long-Term Investments rose 41.9% year-over-year to $413.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $413.1 million (up 41.9% YoY) and the FY2025 annual result came in at $404.5 million, up 18.39% from the prior year.
- Long-Term Investments was $413.1 million for Q1 2026 at Innoviva, up from $404.5 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $544.4 million in Q1 2022 and bottomed at $291.1 million in Q1 2025.
- A 5-year average of $412.0 million and a median of $413.1 million in 2026 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2025 — Long-Term Investments sank 38.91% — and 2026, when it soared 41.9%.
- Innoviva's Long-Term Investments stood at $363.9 million in 2022, then rose by 22.14% to $444.4 million in 2023, then dropped by 23.12% to $341.7 million in 2024, then increased by 18.39% to $404.5 million in 2025, then increased by 2.12% to $413.1 million in 2026.
- Business Quant data shows INVA's Long-Term Investments at $413.1 million in Q1 2026, $404.5 million in Q4 2025, and $343.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 413.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 413.08 Mn |
| Dec 31, 2025 | 404.50 Mn |
| Sep 30, 2025 | 343.79 Mn |
| Jun 30, 2025 | 297.28 Mn |
| Mar 31, 2025 | 291.10 Mn |
| Dec 31, 2024 | 341.66 Mn |
| Sep 30, 2024 | 434.17 Mn |
| Jun 30, 2024 | 444.66 Mn |
| Mar 31, 2024 | 476.55 Mn |
| Dec 31, 2023 | 444.43 Mn |
| Sep 30, 2023 | 422.49 Mn |
| Jun 30, 2023 | 397.94 Mn |
| Mar 31, 2023 | 400.89 Mn |
| Dec 31, 2022 | 363.86 Mn |
| Sep 30, 2022 | 489.11 Mn |
| Jun 30, 2022 | 494.10 Mn |
| Mar 31, 2022 | 544.44 Mn |
| Dec 31, 2021 | 483.85 Mn |
| Sep 30, 2021 | 507.12 Mn |
| Jun 30, 2021 | 473.68 Mn |